FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number: 3235-028						
stimated average burden						
ours per response.	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)															
Name and Address of Reporting Person * Kang Y Michele				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RXHN.OB]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director Officer (give title below) Other (specify below)				
		(First) ARMACEUTICA ER DRIVE		3. Date of 06/30/2		arliest Tr	ansact	ion (M	Ionth/Da	ay/Ye	ear)						
(Street) ROCKVILLE, MD 20850				4. If Amendment, Date Original Filed(Month/Day/Year)							//Year)	_X	6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Cit	(y)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic								ficially Owne	d				
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if any (Month/Day/Year)		Date, if	(Instr. 8)		(A (Im	4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5) (A) or		of (D) Ow Tra (In:	Transaction(s) Instr. 3 and 4) For Instr. 3 (I)		Ownership of Sorm: B Oirect (D) Or Indirect (I)	eneficial wnership		
							Coc	de	V An	nount	(D)	Price				Instr. 4)	
Reminder:	Report on a	separate line for eac	h class of securities Table II -					Po in di	ersons this fo	orm a	are not re urrently v	equired t /alid OM	o respond 3 control r	unless the	tion contair e form	ned SEC 14	74 (9-02)
						alls, war	rants,	, optio	ons, con	vertik	ble securi	ties)					
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	Execution Date, if	Transaction Deriv Code Secur (Instr. 8) Acqu or Di of (D (Instr.		Derivati Securiti	vative rities (I sposed P) . 3, 4,		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title at of Under Securities (Instr. 3 a			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exerc	cisable	Exp Date	viration e	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Options (right to buy)	\$ 1.20							05/0	01/2007	05/0	01/2016	Commo Stock	n 20,000		20,000	D	
Stock Options (right to buy)	\$ 1.40							06/1	1/2007	06/	11/2017	Commo Stock	n 20,000		20,000	D	
Stock Options (right to buy)	\$ 3.24	06/30/2008		A		20,000)		(1)	06/3	30/2018	Commo Stock	20,000	\$ 0	20,000	D	
Stock Options (right to buy)	\$ 1.47	08/12/2008		A		150,00	0		<u>(2)</u>	08/	12/2018	Commo Stock	n 150,000	\$ 0	150,000	D	

Reporting Owners

Donastina Commun Name / Addison	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Kang Y Michele C/O REXAHN PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	X						

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Y. Michele Kang	08/27/2008
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest and become exercisable in full on June 30, 2009.
- (2) 30% of the options vest and become exercisable on August 12, 2009; another 30% of the options vest and become exercisable on August 12, 2010; and the remaining 40% of the options vest and become exercisable on August 12, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.